Nootropics Index - Save on smarter supplements
Isolated phytochemicals & plant compounds

Dihydromyricetin

Dihydromyricetin (DHM)

Dihydromyricetin (DHM, also called ampelopsin) is a flavonoid sold for alcohol-recovery, liver and metabolic claims. The best human evidence is not nootropic: small studies in nonalcoholic fatty liver disease and type 2 diabetes reported changes in liver enzymes, glucose or LDL markers. Alcohol and hangover claims are still mostly animal/mechanistic, and direct human memory, focus or mood evidence is weak. It is not a sobriety aid and cannot make driving safe after alcohol.

GabaergicAntioxidant PathwaysInflammation PathwaysGlucose MetabolismInsulin Sensitivity RelatedStandardized ExtractIsolated Compound
Updated August 2026/5 min read/8 citations
Reviewed by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
01

What is it?

What DHM is

1

Dihydromyricetin is a flavonoid polyphenol also called ampelopsin. It occurs in plants such as Ampelopsis grossedentata, Hovenia dulcis and related herbal products, but many retail products sell purified or enriched DHM rather than whole plant material.

Alcohol marketing is ahead of human evidence7
DHM is often sold as a hangover or alcohol-recovery ingredient. The strongest alcohol-related publication is animal/mechanistic work, while an independent review of hangover products warned that marketed ingredients often lack product-level safety and efficacy evidence. Do not treat DHM as a sobriety tool.

Human evidence is mostly metabolic

3

The clearest human findings are outside nootropics. In a small NAFLD trial, 150 mg twice daily for 3 months changed selected liver enzyme, fasting glucose, LDL and inflammatory markers versus placebo without changing ultrasound-rated liver fat. A separate type 2 diabetes study used a DHM-containing Ampelopsis grossedentata preparation for 1 month and reported glycemic-control signals.

02

Names, aliases and forms

Common NameDihydromyricetin
AbbreviationDHM
Chemical NamesAmpelopsin; Ampeloptin
Pubchem Cid161557
Molecular FormulaC15H12O8
InchikeyKJXSIXMJHKAJOD-LSDHHAIUSA-N
Botanical FamilyAmpelopsis grossedentata / vine tea source context
03

Mechanisms of action

GABA and alcohol models are not human hangover proof

5

The 2012 Journal of Neuroscience paper tested DHM in rats and linked lower alcohol intake, intoxication and withdrawal-like signs to GABA-signaling effects. Another rat/in vitro study did not find clear alcohol-metabolism or alcohol-liver-injury protection in its model. For consumers, that means alcohol claims should stay mechanistic and uncertain.

04

Potential effects and evidence map

DHM has short human studies in metabolic and liver-marker contexts, not in cognition. LiverTox summarizes a placebo-controlled NAFLD study and a type 2 diabetes study that reported selected biomarker changes during short study windows. Alcohol-intoxication findings are mainly animal GABA-signaling research, and an independent review found marketed hangover products often lack adequate clinical support. Direct healthy-user memory, focus, mood and productivity evidence was not identified.

Effect domainMagnitudeGrade
Memory / learning7
UnknownConfidence: Medium

Direct human evidence that DHM improves memory or learning in healthy users was not identified.

Note Brain-injury and GABA-signaling data are mostly animal/mechanistic.

0/5
E
Focus / attention7
UnknownConfidence: Medium

No reliable human focus or productivity evidence was identified.

Note Do not infer focus benefit from alcohol-recovery marketing.

0/5
E
Mental energy / wakefulness7
UnknownConfidence: Medium

DHM is not supported as a mental-energy or wakefulness aid.

Note Alcohol-related marketing should not be translated into performance claims.

0/5
E
Cellular / long-term brain support5
CumulativeConfidence: Low

Antioxidant and anti-inflammatory mechanisms are plausible, but human brain-outcome evidence is weak.

Note Mechanism and animal evidence only.

1/5
D
Physical energy / endurance7
UnknownConfidence: Low

No meaningful human evidence was found for exercise performance or physical energy.

Note Metabolic biomarker studies should not be generalized to energy claims.

0/5
E
05

Typical dosages and timing

Typical
150-760 mg/day
Not a recommendation
Lower bound
150 mg/day
Profile value
Upper bound
760 mg/day
Profile value
Label comparison context2300-1000 mg/day

LiverTox reports common commercial oral labels from 300 to 1,000 mg daily. Human studies include 150 mg twice daily in NAFLD and a DHM-containing preparation providing 760 mg per day in type 2 diabetes. These reports are label-comparison context, not established cognition or hangover-use directions.

06

Timing & effect horizon

Effect horizonUnknown
Unknown
Study window3Acute
4-12 weeks
07

Safety, side effects and risk profile

Not a sobriety or safety tool5
DHM should not be used to keep drinking, judge intoxication, drive after alcohol, or delay urgent care. Even if a product changes how someone feels, it does not prove safer judgment, coordination, reaction time, or blood alcohol clearance.
Short-term safety looks reassuring but incomplete2
LiverTox reports no clinical case reports of DHM-attributed jaundice-level liver injury and gives an unlikely likelihood score for clinically apparent liver injury. That does not establish long-term safety, pregnancy/nursing safety, product purity, or safety in people with liver disease or heavy alcohol exposure.
Evidence uncertainty7
Confidence: High

Consumer alcohol-recovery and nootropic claims run ahead of human efficacy evidence; the strongest human data are metabolic/liver-marker studies.

Note Separate biomarker findings from hangover or cognition promises.

4/5
C
Sedation / impairment5
Confidence: Medium

DHM cannot be used to make alcohol use, driving, or other safety-sensitive activity safe.

Note Animal alcohol-intoxication findings do not prove restored impairment judgment in humans.

3/5
D
Liver / kidney caution2
Confidence: Medium

LiverTox rates DHM as an unlikely cause of clinically apparent liver injury, but people with liver disease or heavy alcohol exposure should not self-manage with concentrated products.

Note Few prospective safety trials exist.

2/5
C
Pregnancy / lactation caution2
Confidence: Medium

Gestation, nursing and pediatric safety data are inadequate for concentrated DHM products.

Note Avoid self-directed use in these groups.

3/5
D
GI discomfort2
Confidence: Low

Short human studies reported no adverse events, but digestive intolerance remains possible with concentrated flavonoid products.

Note Start with product-label context and stop if persistent symptoms occur.

1/5
D
08

Practical buying and quality notes

  • Prefer products that disclose the DHM amount per serving, plant source, purity or standardization, heavy-metal and microbial testing, and third-party verification. Be skeptical of blends where DHM is hidden inside a proprietary hangover formula with many other ingredients and no exact amount.7
09

FAQ

Does DHM reduce hangover symptoms?

7

Human evidence is not strong enough to say that. DHM is common in hangover products, but product-level trials and transparent dosing are often missing.

Is DHM a nootropic?

5

Not in the usual evidence-based sense. Direct human data for memory, focus or mental energy are weak; most brain-related claims come from animal or mechanism studies.

What human dose has been studied?

2

Published examples include 150 mg twice daily in a NAFLD trial and a DHM-containing preparation providing 760 mg per day in a type 2 diabetes study. LiverTox also describes a broad commercial oral-label range.

Who should avoid casual DHM use?

2

People with liver disease, heavy alcohol exposure, pregnancy or nursing status, complex prescription-drug regimens, or any safety-sensitive alcohol context should avoid self-directed DHM use and seek qualified clinical guidance.

10

References

  1. PubChem. Compound Summary for CID 161557, Dihydromyricetin.
  2. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Dihydromyricetin. Last update August 16, 2023.
  3. Chen S, Zhao X, Wan J, Ran L, et al. Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: a randomized controlled trial. Pharmacological Research. 2015.
  4. Ran L, Wang X, Lang H, Xu J, et al. Ampelopsis grossedentata supplementation effectively ameliorates the glycemic control in patients with type 2 diabetes mellitus. European Journal of Clinical Nutrition. 2019.
  5. Shen Y, Lindemeyer AK, Gonzalez C, Shao XM, et al. Dihydromyricetin as a novel anti-alcohol intoxication medication. Journal of Neuroscience. 2012.
  6. Skotnicova A, Boubinova G, Bostikova Z, et al. Does dihydromyricetin impact on alcohol metabolism. Physiological Research. 2020.
  7. Verster JC, van Rossum CJI, Scholey A. Unknown safety and efficacy of alcohol hangover treatments puts consumers at risk. Addictive Behaviors. 2021.
  8. ClinicalTrials.gov. NCT05623501, Phase I dose-escalation study of dihydromyricetin in healthy volunteers / alcohol-associated liver disease context.
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.